July 22 (Reuters) – Switzerland’s Lonza, the world’s largest contract drug manufacturer, raised the full-year target for its core profit margin to between 33% and 34% on Wednesday, citing strong operational execution and contributions from maturing growth projects.
It had previously expected its core earnings before interest, taxes, depreciation and amortization margin to expand to more than 32% of sales this year.
(Reporting by Bartosz Dabrowski and Kira Britten, editing by Milla Nissi-Prussak)
Brought to you by www.srnnews.com